Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Comparative evaluation of the efficiency of a sumatriptan/dexketoprofen combination versus sumatriptan monotherapy in the treatment of a migraine attack

Full Text:


Migraine is a chronic brain disease with a high prevalence and a marked deterioration in quality of life. Triptans are the gold standard for migraine attack therapy, but they are not effective in all patients. The aim of an observational program was to compare a sumatriptan/dexketoprofen combination and sumatriptan monotherapy for attack relief. Patients and methods. The observation program included 38 migraine patients. A migraine attack was relieved with a combination of sumatriptan 100 mg and dexketoprofen 25 mg in 20 patients and with only sumatriptan 100 mg in 18 patients (Group 2). All the study participants filled out a questionnaire in which they indicated the time of attack onset, the time of drug intake, the intensity of pain, and the presence of concomitant symptoms (nausea, phono-and photophobia) before and 0.5, 1, 2, 4, 8, and 24 hours after drug administration. The investigators estimated the key indicators of the observation program: pain relief at 2, 4, 8, and 24 hours and a significant decrease in pain intensity at 30 minutes, 1 and 2 hours. Therapy satisfaction was determined using the Patient Perception of Migraine Questionnaire (PPMQ) that the patients filled out at 24 hours after the attack. Results. A larger number of patients receiving combined therapy with sumatriptan 100 mg and dexketoprofen 25 mg noted a significant decrease in the intensity of headache at 1 hour and the absence of pain at 2 and 4 hours compared with those in the sumatriptan monotherapy group. According to the PPMQ questionnaire, the combined therapy group showed higher treatment satisfaction. Conclusion. The combination of sumatriptan 100 mg and dexketoprofen 25 mg was shown to have some advantage over sumatriptan 100 mg monotherapy in treating migraine attack. The results of the observation program are correlated with those of previous studies. The higher efficiency of combined therapy with triptan + nonsteroidal anti-inflammatory drugs versus that of monotherapy with triptans reflects a variety of pathophysiological processes that accompany a migraine attack, as well as the presence of several targets for pathogenetic therapy.

About the Authors

K. V. Skorobogatykh
OOO «University Clinic of Headache», Moscow
Russian Federation

Yu. E. Azimova
OOO «University Clinic of Headache», Moscow
Russian Federation


1. Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev. 2017 Apr;97(2):553-622. doi: 10.1152/physrev.00034.2015.

2. Lipton RB, Bigal ME, Diamond M, et al; Advisory Group AMPP. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007 Jan 30;68(5):343-9.

3. Ayzenberg I, Katsarava Z, Sborowski A, et al; Lifting the Burden. The prevalence of primary headache disorders in Russia: a countrywide survey. Cephalalgia. 2012 Apr;32(5):373-81.

4. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016 Oct 8;388(10053):1545-1602. doi: 10.1016/ S0140-6736(16)31678-6.

5. Linde M, Gustavsson A, Stovner LJ, et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. 2012 May; 19(5):703-11.

6. Ayzenberg I, Katsarava Z, Sborowski A, et al. Headache-attributed burden and its impact on productivity and quality of life in Russia: structured healthcare for headache is urgently needed. Eur J Neurol. 2014 May;21(5):758-65.

7. doi: 10.1111/ene.12380. Epub 2014 Feb 13.

8. Evers S, Afra J, Frese A, et al; European Federation of Neurological Societies. EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur J Neurol. 2009 Sep;16(9):968-81. doi: 10.1111/j. 1468-1331.2009.02748.x.

9. Tfelt-Hansen P1, Pascual J, Ramadan N, et al; International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: Third edition. A guide for investigators. Cephalalgia. 2012 Jan;32(1):6-38.

10. Осипова ВВ, Филатова ЕГ, Артеменко АР и др. Диагностика и лечение мигрени: рекомендации российских экспертов. Журнал неврологии и психиатрии им. С.С.Корсакова. 2017;117(1-2):28-42. [Osipova VV, Filatova EG, Artemenko AR, et al. Diagnosis and treatment of migraine: recommendations of Russian experts. Zhurnal nevrologii i psikhiatrii im. S.S.Korsakova. 2017;117(1-2):28-42. (In Russ.)].

11. Скоробогатых КВ, Табеева ГР. Кальцитонин-ген-родственный пептид в патогенезе первичных головных болей. Российский журнал боли. 2010;(1):1–52. [Skorobogatykh KV, Tabeeva GR. Calcitonin-gene-related peptide in the pathogenesis of primary headaches. Rossiiskii zhurnal boli. 2010; (1):1–52. (In Russ.)].

12. Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies – successful translation from bench to clinic. Nat Rev Neurol. 2018 Jun;14(6): 338-350. doi: 10.1038/s41582-018-0003-1.

13. Williamson DJ, Hargreaves RJ. Neurogenic inflammation in the context of migraine. Microsc Res Tech. 2001 May 1;53(3):167-78.

14. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol. 2004 Jan;55(1):19-26.

15. Buzzi MG, Sakas DE, Moskowitz MA. Indomethacin and acetyl salicylic acid block neurogenic plasma protein extravasation in rat dura mater. Eur J Pharmacol. 1989 Jun 20; 165(2-3):251-8.

16. Kaube H, Williamson D, Cumberbatch M, et al. Cyclooxygenase (COX-1) inhibition with ketorolac blocks central trigeminal transmission but not CGRP-release from peripheral trigeminal sensory neurons. Cephalalgia. 2000;20(4):283

17. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/ 1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002 Oct;22(8):633-58.

18. Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current understanding and treatment. N Engl J Med. 2002 Jan 24;346(4):257-70.

19. Krymchantowski AV. Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arq Neuropsiquiatr. 2000 Jun;58(2B):428-30.

20. Krymchantowski AV, Barbosa JS. Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Cephalalgia. 2002 May; 22(4):309-12.

21. Smith TR1, Sunshine A, Stark SR, et al. Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine. Headache. 2005 Sep;45(8):983-91.

22. Tullo V, Valguarnera F, Barbanti P, et al. Comparison of frovatriptan plus dexketoprofen (25 mg or 37.5 mg) with frovatriptan alone in the treatment of migraine attacks with or without aura: a randomized study. Cephalalgia. 2014 May;34(6):434-45

23. Moore RA, Barden J. Systematic review of dexketoprofen in acute and chronic pain. BMC Clin Pharmacol. 2008 Oct 31;8:11.

24. doi: 10.1186/1472-6904-8-11.

25. Karacabey S, Sanri E, Yalcinli S, Akoglu H. Which is more effective for the treatment of Acute Migraine Attack: Dexketoprofen, Ibuprofen or Metoclopramide? Pak J Med Sci. 2018 Mar-Apr;34(2):418-423. doi: 10.12669/ pjms.342.13815.

26. Gungor F, Akyol KC, Kesapli M, et al. Intravenous dexketoprofen vs placebo for migraine attack in the emergency department: A randomized, placebo-controlled trial. Cephalalgia. 2016 Feb;36(2):179-84. doi: 10.1177/ 0333102415584604. Epub 2015 May 5.

27. Barbanoj MJ, Antonijoan RM, Gich I. Clinical pharmacokinetics of dexketoprofen. Clin Pharmacokinet. 2001;40(4):245-62.

28. Инструкция к препарату Фламадекс. [The instruction to the drug Flamadex]

29. Headache Classification Committee of the International Headache Society. The international classification of headache disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211. doi: 10.1177/0333102417738202.

30. Kimel M, Hsieh R, McCormack J, et al Validation of the revised Patient Perception of Migraine Questionnaire (PPMQ-R): measuring satisfaction with acute migraine treatment in clinical trials. Cephalalgia. 2008 May;28(5): 510-23. doi: 10.1111/j.1468-2982.2007.01524.x. Epub 2008 Mar 31.

31. Allais G, Rolando S, De Lorenzo C, Benedetto C. The efficacy and tolerability of frovatriptan and dexketoprofen for the treatment of acute migraine attacks. Expert Rev Neurother. 2014 Aug;14(8):867-77. doi: 10.1586/ 14737175.2014.940901.

32. Law S, Derry S, Moore RA. Sumatriptan plus naproxen for acute migraine attacks in adults. Cochrane Database Syst Rev. 2013 Oct 21; (10):CD008541. doi: 10.1002/14651858. CD008541.pub2.

33. Алексеева ЛИ, Таскина ЕА, Кашеварова НГ и др. Оценка эффективности и безопасности ступенчатой терапии декскетопрофена трометамолом у пациентов с острой болью в спине и обострением остеоартрита крупных суставов. Лечебное дело. 2017;(2):66-72. [Alekseeva LI, Taskina EA, Kashevarova NG, et al. Evaluation of efficacy and safety of step therapy with dexketoprofen trometamol in patients with acute back pain and exacerbation of osteoarthritis of large joints. Lechebnoe delo. 2017;(2):66-72. (In Russ.)].


For citations:

Skorobogatykh K.V., Azimova Yu.E. Comparative evaluation of the efficiency of a sumatriptan/dexketoprofen combination versus sumatriptan monotherapy in the treatment of a migraine attack. Neurology, Neuropsychiatry, Psychosomatics. 2018;10(3):42-47. (In Russ.)

Views: 850

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)